Current strategies to target prostate cancer are based on differential expression of prostate-associated genes (e.g. PSA; prostatic acid phospahatase (PAcP); prostate specific stem cell antigen (PSCA); androgen receptor (AR), etc.). This evidence concerns the gene PSCA and prostate cancer.